Effect of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein(a) still to be unravelled

Abstract

Get full access to this article

View all access options for this article.

References

Zenti

Altomari

Lupo

et al.

From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol 2018; 25: 1843–1851.

Otto

Geiss

Empen

et al.

Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis 2004; 174: 151–156.

Adorni

Zimetti

Puntoni

et al.

Cellular cholesterol efflux and cholesterol loading capacity of serum: Effects of LDL-apheresis. J Lipid Res 2012; 53: 984–989.

Sbrana

Bigazzi

Dal Pino

et al.

Elusive therapeutic effect of PCSK9 inhibitors on lipoprotein(a) levels. Ther Apher Dial. Epub ahead of print 11 October 2018. DOI: 10.1111/1744-9987.12766.